Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05861076 · ClinicalTrials.gov registry record · NA

Moringa Powder Acceptability Trial Among Healthy Adults

A NA study of Acceptability and Side Effect, sponsored by University of California, Berkeley.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT05861076: Completed NA study of Acceptability and Side Effect, sponsored by University of California, Berkeley.

NCT05861076 is a NA study of Acceptability and Side Effect that has completed, run by University of California, Berkeley. The registered enrollment target is 52 participants, above the 47-participant average among 4 other Acceptability trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05861076, a NA study of Acceptability and Side Effect, has completed, sponsored by University of California, Berkeley.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The study is a randomized acceptability trial involving the provision of three different doses of Moringa powder to be consumed daily by study participants.

Primary Outcome

Total number of days that moringa powder was consumed

Conditions Studied

Acceptability Side Effect Consumption

Interventions

  • OTHER Moringa Powder - Low Dose
  • OTHER Moringa Powder - Medium Dose
  • OTHER Moringa Powder - High Dose

Study Locations (1)

California

  • University of California - Berkeley

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2023-01-03
Est. Completion 2023-05-30
Phase NA
University of California, Berkeley

72 total trials

What the finished NCT05861076 record still lists

NCT05861076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, above the 47-participant average among 4 other Acceptability trials with a reported enrollment target (11% higher).

The record links to 3 conditions, with Acceptability appearing as the primary indexed condition, and to 3 interventions - of which Moringa Powder - Low Dose is the first listed.

NCT05861076 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05861076 about?

NCT05861076 is a clinical study titled "Moringa Powder Acceptability Trial Among Healthy Adults". The study is a randomized acceptability trial involving the provision of three different doses of Moringa powder to be consumed daily by study participants.

What is the current status of trial NCT05861076?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2023-01-03. Estimated completion is 2023-05-30.

What conditions does trial NCT05861076 study?

This clinical trial studies the following conditions: Acceptability, Side Effect, Consumption.

What interventions are being tested in trial NCT05861076?

The interventions under investigation include: Moringa Powder - Low Dose (OTHER), Moringa Powder - Medium Dose (OTHER), Moringa Powder - High Dose (OTHER).

Who is sponsoring clinical trial NCT05861076?

This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05861076 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acceptability

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05861076, the US trial registry maintained by the National Library of Medicine. NCT05861076 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.